Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07502066

Clinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases

The goal of this one blind-randomized controlled clinical trial is to evaluate the clinical effectiveness of a telerehabilitation (TR) protocol focusing on balance rehabilitation in patients with neurodegenerative diseases (Parkinson's Disease, Multiple Sclerosis).

The secondary objectives of the study are:

1. To evaluate the effects of clinical treatment on Health-Related Quality of Life (HRQOL) outcomes. 2. To collect data on process measures: user needs (patients and caregivers), treatment adherence, usability, satisfaction, technological acceptance.

Participants will perform 20 rehabilitation session (physiotherapy) for balance improvement. Experimental group patients will be trheated through tele-rehabilitation performing exercise with an hospital physiotherapist.

Researchers will compare telerehabilitation group to usual care group to see if there is a significant improvement in motor function, particularly in balance and mobility tests, as well as an improvement in quality of life.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

About this study

Single-blind randomised controlled clinical trial. A sample of 36 consecutive patients (18 per group) suffering from Multiple Sclerosis (N=18, 9 per group) and Parkinson's Disease (N=18, 9 per group), admitted to the San Camillo IRCCS Hospital in Venice in ordinary inpatient or outpatient care, who still need home rehabilitation, will be enrolled. patients will be randomised to receive either TR or usual care, based on an allocation generated by the website: "Sealed Envelope.com". After discharge and before treatment (T1), a researcher will conduct blinded clinical assessments, repeated after 20 rehabilitation sessions (T2), and 2 months after the end of treatment (T3). The rehabilitation modality provided by the IRCCS in telerehabilitation is based on virtual reality modalities. In particular, the experimental treatment under study involves the use of the VRRS-TR system (Khymeia Group s.r.l, Noventa Padovana), which consists of

  • n.1 Tablet complete with keyboard, power supply, telerehabilitation application (Virtual Reality Rehabilitation System- VRRS);
  • no.1 multi-USB device with cable for USB-mini port
  • n.1 video camera;
  • no.1 wide-angle lens and its attachment;
  • no.1 K-wand;
  • no.2 KHIMU wireless inertial sensors with power supply
  • 1 USB dongle for communication with KHIMU sensors
  • n.7 Velcro strips These technologies will be delivered to the patient and will be used at home, through a two-way on-line connection by means of Synchronous Telerehabilitation, with an IRCCS physiotherapist, who will deliver the treatments through a dedicated workstation (Telecokpit), with which it will be possible to manage the patient's tablet through the "Teamviewer" app, interacting with the latter and monitoring the execution of the exercises through the videoconference implemented in the system.

The virtual environment makes it possible to administer a high dose of repetitions of the movement of interest; for each exercise, the quality of execution is monitored in real time, i.e. through the return of feedback to the subject through visual, acoustic and vocal indications. Finally, various parameters, such as the distance of the targets to be reached, the sensitivity, the number of repetitions and the dwell time on the different targets, allow the difficulty of the exercise to be increased or decreased. In order to perform the rehabilitation protocol in telerehabilitation, inertial sensors (KhyMU) are used, which are applied to the part of the body that will become the effector of the movement. The sensors are applied using special elastic bands on the front part of the trunk and the front part of the thighs/legs/arms. Depending on the movement to be trained, the therapist decides whether to use one sensor or both.The exercises proposed to the control group will be performed by the latter at home, in self-treatment. Type, intensity, duration and objectives of these exercises are structured to be as similar and homogeneous as possible to those performed by means of the VRRS system in Telerehabilitation. In order to carry out the therapies, the patient will be given a booklet with a precise description of the exercises to be performed accompanied by explanatory pictures. This file is created through the website: www.physiotherapyexercises.com. On a weekly basis, a physiotherapist will contact the patient by telephone to inquire about the progress of the therapies, giving indications on how to modify the modalities, number of repetitions, duration and difficulty of the exercises, maintaining the logic of incremental training adopted in the TR group protocol. The patient will also be provided with a monitoring diary of the activities performed, corresponding to the automatic reporting system implemented in the VRRS system, used instead for the TR group.

Follow-up (T3) At the end of the treatment protocol, two months after the final evaluation (T2), a Follow-Up will be carried out by means of a brief telephone survey to monitor the state of health, autonomy in ADLs, number of falls and perception of safety with respect to one's own balance of the patients enrolled in this project.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Possession of an ADSL internet connection with a flat rate or, in the case of a pay-as-you-go tariff, with an availability of at least 20 Gigabytes/month.

PARKINSON'S DISEASE:

  • Patients with Parkinson's disease, according to the criteria of the UK Parkinson's Disease Society Brain Bank, in stabilised pharmacological treatment with L-Dopa or dopamine agonists and with a Hoehn & Yahr scale score between 1.5 and 2.5;
  • Patients presenting a score ≤ 2 in the 'freezing when walking' subitem of section II of the UPDRS;
  • Patients presenting a score ≤ 2 in both duration and disability in the "dyskinesias" sub-item of section IV of the UPDRS.

MULTIPLE SCLEROSIS

  • Subjects with Multiple Sclerosis (MS) in the relapsing remitting (RRMS) or secondary progressive (SPMS) forms, according to the criteria of MC Donald 2010 [14], under stable drug treatment and with Expanded Disability Status Scale (EDSS) score ≤ 6.5;
  • At the time of inclusion, at least 3 months have elapsed since the last relapse.

Exclusion criteria

  • All patients will be excluded from the study who, in association with the diagnosis of the diseases listed above, have the following comorbidities diagnosed and documented in the medical records
  • Unstabilised fractures;
  • Diagnosis of major depression;
  • Severe deficits in visual acuity and hearing perception;
  • Dementia;
  • Epilepsy not controlled pharmacologically;
  • Ideomotor apraxia;
  • Neglect;
  • Severe impairment of verbal comprehension

Treatment and study plan

Telerehabilitation Treatment

Other

The treatment will last 4 weeks; each session will be1 hour, to be performed five times a week. Patients in the Telerehabilitation group will perform the same balance rehabilitation protocol as the controls, through the telerehabilitation system implemented by the IRCCS, which allows them to perform rehabilitation treatments at home, monitored by a hospital physiotherapist. Both groups will carry out a clinical evaluation before and after the treatments and will be contacted again briefly two months after the end of the treatment to ascertain the maintenance of the results obtained.

Other names: remote rehabilitation

conventional treatment

Other

The conventional treatment group will perform a programme of exercises, specific for balance, contained in a booklet, in which there is a description of the activities, accompanied by explanatory pictures. On a weekly basis, a physiotherapist will contact the individuals in this group by telephone to inquire about the progress of the therapy, and provide information on how to possibly modify the mode, number of repetitions, duration and difficulty of the exercises. In addition, the patient will be provided with a diary to monitor the activities performed. The treatment will last four weeks; each session will be one hour, to be performed five times a week.

Other names: usual care treatment

Primary outcomes

  1. Berg Balance Scale

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    The Berg Balance Scale (BBS) objectively assesses a patient's ability to safely maintain balance during 14 predetermined tasks. Each item is scored on a 5-point ordinal scale (0-4), with 0 indicating the lowest level of function and 4 the highest. The assessment takes approximately 20 minutes and excludes gait evaluation.

    Possible scores range from 0 to 56, with higher scores indicating better balance function.

Secondary outcomes

  1. Mini-Balance Evaluation System Test (Mini-BESTest)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    The Mini-BESTest evaluates dynamic balance, functional mobility, and gait through 14 items across four sections: anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait.

    Possible scores range from 0 to 28, with higher scores indicating better postural control and balance function.

  2. Functional Ambulation Classification (FAC)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    FAC is a 6-point functional walking test that evaluates ambulation ability by determining the level of human support required when walking, regardless of assistive devices used.

    Scores range from 0 (non-functional ambulator) to 5 (independent ambulator on any surface), with higher scores indicating better independence in ambulation.

  3. 5X Sit-to-Stand Test (5XSST)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    5x Sit-To-Stand Test assesses functional lower extremity strength, transitional movements, balance, and fall risk, measuring the time taken to rise from a chair 5 times.

    Scores are time in seconds (typically 5-30 seconds in adults), with lower time ndicating better lower limb strength and balance.

  4. Activities specific-Balance Confidence (ABC) -Scale

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

    ABC scale is s a 16-item questionnaire measuring confidence in performing ambulatory activities without losing balance or feeling unsteady.

    Scores range from 0% (no confidence) to 100% (complete confidence), with higher scores indicating greater balance confidence.

  5. Barthel Index (BI)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    BI is an ordinal scale measuring performance in 10 activities of daily living (ADL) and mobility, based on time and assistance required.

    Scores range from 0 (total dependence) to 100 (complete independence), with higher scores indicating better functional independence.

  6. Six Minutes Walking Test (6MWT)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline

    6MWT is a sub-maximal exercise test assessing aerobic capacity and endurance by measuring distance covered in 6 minutes.

    Scores are distance in meters (typically 300-700m in adults), with greater distances indicating better endurance.

  7. Ten metres walking test (10MWT)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    10MWT assesses walking speed in meters per second over a short distance to evaluate functional mobility, gait, and vestibular function.

    Scores are time in seconds or speed in m/s (typically 0.8-1.5 m/s), with faster speeds (lower times) indicating better gait performance.

  8. Short-Form-36 health outcome (SF-36)

    Time frame: Change from Baseline (T1) to Post-intervention (T2), approximately 6 weeks after baseline.

    SF-36 is a self-reported measure of health-related quality of life across eight domains, yielding Physical Component Summary (PCS) and Mental Component Summary (MCS) scores.

    Domain scores range 0-100; PCS and MCS standardized to mean 50 (SD 10), with higher scores indicating better health status.

  9. Falls questionnaire (last year-last 2 months)

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

    Self-produced questionnaire monitoring the number of falls occurring during the previous year and the two months prior to administration, including circumstances of falls.

    Scores are count of falls (0 or more), with fewer falls indicating better outcome.

  10. EuroQol-5 Dimensions, 3 Levels (EQ-5D-3L)

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

    The EQ-5D is a self-completion questionnaire assessing health-related quality of life across five dimensions plus a visual analog scale, yielding an index score.

    Index scores range from -0.594 (worse than dead) to 1 (perfect health), with higher scores indicating better health status.

  11. Instrumental Activities of Daily Living (IADL)

    Time frame: Change from Baseline (T1) to Follow-up (T3), approximately 12 weeks after baseline.

    IALS assesses ability to perform complex community-living tasks independently (Lawton scale).

    Scores range from 0 (low functioning, dependent) to 8 (high functioning, independent), with higher scores indicating better independence.

  12. Client Satisfaction Measure Questionnaire (SMQ)

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

    Custom questionnaire measuring patient satisfaction with the received therapy. Scores range to be specified (e.g., 0-100 if Likert-based), with higher scores indicating greater satisfaction.

  13. System Usability Scale (SUS)

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

    The System Usability Scale (SUS) is a 10-item questionnaire providing a reliable measure of system usability.

    Scores range from 0 to 100, with higher scores indicating better perceived usability (≥68 acceptable).

  14. Technology acceptance questionnaire (TAM)

    Time frame: At Post-intervention (T2), approximately 6 weeks after baseline.

    Custom questionnaire based on the Technology Acceptance Model (TAM), measuring patient acceptance of the technology used through constructs like perceived usefulness, perceived ease of use, and behavioral intention.

    Individual items scored on a 7-point Likert scale (1=strongly disagree to 7=strongly agree); composite/mean scores range from 1 to 7, with higher scores indicating greater technology acceptance.

Sponsors and collaborators

Lead sponsor

IRCCS San Camillo, Venezia, Italy

Other

Registry information

Acronym: LIDO

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.